Mostrar o rexistro simple do ítem

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

dc.contributor.authorVerger, A.*
dc.contributor.authorYakushev, I.*
dc.contributor.authorAlbert, N.L.*
dc.contributor.authorvan Berckel, B.*
dc.contributor.authorBrendel, M.*
dc.contributor.authorCecchin, D.*
dc.contributor.authorAguiar Fernández, Pablo*
dc.contributor.authorFraioli, F.*
dc.contributor.authorGuedj, E.*
dc.contributor.authorMorbelli, S.*
dc.contributor.authorTolboom, N.*
dc.contributor.authorTraub-Weidinger, T.*
dc.contributor.authorVan Weehaeghe, D.*
dc.contributor.authorBarthel, H.*
dc.date.accessioned2025-09-09T11:22:57Z
dc.date.available2025-09-09T11:22:57Z
dc.date.issued2023
dc.identifier.citationVerger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. Vol. 50, European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media Deutschland GmbH; 2023. pp. 1553-5.
dc.identifier.issn1619-7089
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/6416a7b25db420433b7b9fca
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21502
dc.description.sponsorshipOpen Access funding enabled and organized by Projekt DEAL.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshNeuroimaging *
dc.subject.meshPositron-Emission Tomography *
dc.subject.meshAmyloid *
dc.subject.meshAlzheimer Disease *
dc.subject.meshAmyloid beta-Peptides *
dc.titleFDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective
dc.typeArtigo
dc.authorsophosVerger, A.; Yakushev, I.; Albert, N.L.; van Berckel, B.; Brendel, M.; Cecchin, D.; Fernandez, P.A.; Fraioli, F.; Guedj, E.; Morbelli, S.; Tolboom, N.; Traub-Weidinger, T.; Van Weehaeghe, D.; Barthel, H.
dc.identifier.doi10.1007/s00259-023-06177-5
dc.identifier.sophos6416a7b25db420433b7b9fca
dc.issue.number6
dc.journal.titleEuropean Journal of Nuclear Medicine and Molecular Imaging*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initial1553
dc.page.final1555
dc.relation.projectIDProjekt DEAL
dc.relation.publisherversionhttps://doi.org/10.1007/s00259-023-06177-5
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordIDIS
dc.typefidesArtículo de Opinión (Editorial, Carta, ?)
dc.typesophosArtículo de Opinión
dc.volume.number50


Ficheiros no ítem

Descargar/
Nome:
1291.pdf
Tamaño:
371.7Kb
Formato:
PDF
Descrición:
Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA ...

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution 4.0 International (CC BY 4.0)
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution 4.0 International (CC BY 4.0)